Showing results (51-60 of 70) with videos related to
Sort By:
Pageof 7
Cancer|June 24, 2006
Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinomaNizar Tannir, Eric Jonasch, Lance C Pagliaro, et al.Cancer|October 7, 2011
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 studyJohn C Araujo, Paul Mathew, Andrew J Armstrong, et al.Urologic Oncology|August 6, 2011
A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancerJianqing Lin, Marianna Zahurak, Tomasz M Beer, et al.Journal of the National Cancer Institute|June 8, 2006
Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancerSun-Jin Kim, Hisanori Uehara, Sertac Yazici, et al.The Journal of Urology|November 18, 2008
Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancerPaul Mathew, Louis L Pisters, Christopher G Wood, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2009
Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortiumJonathan E Rosenberg, Charles J Ryan, Vivian K Weinberg, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancerSue-Hwa Lin, Yu-Chen Lee, Michel B Choueiri, et al.Cancer|August 27, 2014
Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancerMehmet Asim Bilen, Marcella M Johnson, Paul Mathew, et al.Proceedings of the National Academy of Sciences of the United States of America|March 13, 2015
Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptorsJami Mandelin, Marina Cardó-Vila, Wouter H P Driessen, et al.Clinical Genitourinary Cancer|February 14, 2009
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical researchMichael J Morris, Ethan M Basch, George Wilding, et al.Pageof 7